The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis
NCT ID: NCT02614300
Last Updated: 2015-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pulmonary Rehabilitation
These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
Pulmonary Rehabilitation
The patient will come 3 times per week during 12 weeks Each session 45min
Chest Physiotherapy
The ELTGOL technique ("total slow expiration with glottis open in lateral decubitus") for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary.
Chest Physiotherapy
The patient will come 3 times per week during 12 weeks Each session 30min
Pulmonary Rehabilitation and Chest Physiotherapy
This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.
Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs.
Pulmonary Rehabilitation and Chest Physiotherapy
The patient will come 3 times per week during 12 weeks Each session 1h15min
Control Group
For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.
The physiotherapist will also do monthly telephone calls for patient's monitoring.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pulmonary Rehabilitation and Chest Physiotherapy
The patient will come 3 times per week during 12 weeks Each session 1h15min
Pulmonary Rehabilitation
The patient will come 3 times per week during 12 weeks Each session 45min
Chest Physiotherapy
The patient will come 3 times per week during 12 weeks Each session 30min
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No performing regular physiotherapy treatment or physical training (≤ 1 time/week);
* Stable disease \[no changes in the chronic therapy (both inhaled and systematic) in the usual respiratory symptoms (according to the medical evaluation) and spirometry in the last 4 weeks prior to study recruitment\];
* Regular cough and expectoration;
* Ability to follow the exercise program;
* Ability to perform all clinical tests, to understand the process and the purposes of the study;
* A history of at least 2 exacerbations during the previous year requiring antibiotic treatment and;
* Signed informed consent.
Exclusion Criteria
* FEV1 \<30% or/and TLC\<40% ;
* Diagnosis of cystic fibrosis, sarcoidosis, pulmonary fibrosis, active tuberculosis or non tuberculosis mycobacterial infection,
* Diagnosis of asthma or COPD as a primary respiratory disease and associated secondary bronchiectasis,
* Patients with unstable cardiac disease or locomotor difficulties that preclude exercise (eg, severe arthritis or severe peripheral vascular disease);
* Chronic respiratory failure and/or oxygen therapy;
* Frequent haemoptysis (≥ 2 times/month);
* Participation in a PR program during the year prior to inclusion or during the study protocol;
* Participation in a CP program during 1 month prior to inclusion;
* Any physical and psychological disorder that interferes with protocol compliance;
* Participation in a clinical trial implying any change in usual pharmacological treatment in the last 6 months before recruitment;
* Being on the waiting list for lung transplantation or have been transplanted.
50 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sociedad Española de Neumología y Cirugía Torácica
OTHER
Hospital Clinic of Barcelona
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eva Polverino
Specialist in Respiratory Diseases
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Herrero-Cortina B, Alcaraz-Serrano V, Torres A, Polverino E. Reliability and Minimum Important Difference of Sputum Weight in Bronchiectasis. Respir Care. 2020 Oct;65(10):1478-1487. doi: 10.4187/respcare.07175. Epub 2020 Feb 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PulmRehab_NCFBE
Identifier Type: -
Identifier Source: org_study_id